Scientists have made a significant breakthrough in understanding how 'bad' cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body. The researchers were able to show ...
Despite decades of study, a pharmacopoeia of medicines, and untold millions in pharmaceutical research, heart disease remains the leading cause of death around the world. Excess cholesterol in ...
Peter Attia warns that simplicity is crushing nuance in science. I agree—so I took a closer look at his own argument on LDL, ...
Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...
Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.
An experimental pill called enlicitide slashed levels of low-density lipoprotein (LDL) cholesterol, commonly known as "bad" cholesterol, by up to 60%, according to a new phase three clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results